US Supreme Court Will Not Review Contrave Case
Teva’s Actavis Fails To Convince Top Court To Review Split Decision
The US Supreme Court has turned down a request by Teva’s Actavis to review a ruling that upheld a patent protecting Nalpropion’s Contrave until 2030, despite the generics firm pointing out that the exact terms of a patent claim were not present in its specification.
You may also be interested in...
The US Supreme Court has refused a certiorari petition to review a decision involving Dr Reddy’s and Pfizer over Eli Lilly’s Alimta that revolved around the doctrine of equivalents.
Teva has seen two US patents protecting the Contrave combination of naltrexone and bupropion ruled invalid on appeal. But it is no nearer bringing a generic of the weight-loss drug to market, as the Court of appeals upheld a later-expiring patent, albeit on a split decision.
Samsung Bioepis has received an EMA nod for its Sandoz-partnered Stelara biosimilar under the name Pyzchiva. Meanwhile, the agency’s CHMP also recommended granting centralized marketing authorizations for two Accord generics.